'Decade of innovation has transformed biotech sector'

BIOTECH

David Pinniger, manager of Polar Capital's new Biotechnology fund, casts an eye over a rapidly developing and maturing market.

Biotech funds are becoming increasingly popular after a strong run for the asset class. Last year the NASDAQ biotechnology index rose by 61% compared to the S&P 500’s 26% return. As a result, firms are launching products dedicated to investing in biotech companies to take advantage of opportunities in the sector. Fund manager David Pinniger joined Polar Capital in August 2013 and launched the Polar Capital Biotechnology fund at the start of November that year. He was previously fund manager on the International Biotechnology trust, run by SV Life Sciences. Here he outlines curre...